ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,459.10
1.11%
US Tech 100
18,512.80
0.99%
Dow Jones
40,589.34
1.64%
Brent Oil
79.745
-2.20%
Bitcoin
67,960.18
3.31%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Taysha Gene Therapies Inc (TSHA) Quote

Taysha Gene Therapies Inc

Taysha Gene Therapies Inc (TSHA)

NASDAQ
2.30
0.03
(1.32%)
At close: July 26 4:00PM
Delayed by 15 minutes
2.30
0.00
( 0.00% )
After Hours: 4:49PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.30
Bid
2.20
Ask
2.30
Volume
1,087,569
2.205 Day's Range 2.35
0.62 52 Week Range 4.32
Market Cap
430.142M
Previous Close
2.27
Open
2.31
Last Trade
50
@
2.19
Last Trade Time
16:31:09
Financial Volume
$ 2,476,844
VWAP
2.2774
Average Volume (3m)
2,338,971
Shares Outstanding
187,018,275
Dividend Yield
-
PE Ratio
-3.84
Earnings Per Share (EPS)
-0.6
Revenue
15.45M
Net Profit
-111.57M

About Taysha Gene Therapies Inc

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and com... Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.tayshagtx.com
Headquarters
Dover, Delaware, USA
Founded
1970
Taysha Gene Therapies Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TSHA. The last closing price for Taysha Gene Therapies was $2.27. Over the last year, Taysha Gene Therapies shares have traded in a share price range of $ 0.62 to $ 4.32.

Taysha Gene Therapies currently has 187,018,275 shares outstanding. The market capitalization of Taysha Gene Therapies is $424.53 million. Taysha Gene Therapies has a price to earnings ratio (PE ratio) of -3.84.

TSHA Latest News

More News

Form 144 - Report of proposed sale of securities

July 05 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

July 05 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

July 05 2024
Edgar (US Regulatory)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, July 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene...

July 05 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene...

June 26 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene...

June 25 2024
GlobeNewswire Inc.

Form 8-K - Current report

June 18 2024
Edgar (US Regulatory)

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging...

June 18 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, June 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene...

June 07 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

May 31 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.031.321585903082.272.352.112033742.21938209CS
4-0.08-3.361344537822.382.531.9916665322.27931524CS
12-0.35-13.20754716982.654.321.8323389712.89663023CS
260.8356.4625850341.474.321.4125338602.73804077CS
521.629242.7719821160.6714.320.6231438432.41617357CS
156-16.28-87.621097954818.5821.90.514103442.66194187CS
260-19.95-89.662921348322.2533.840.511367413.25372765CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CGTXCognition Therapeutics Inc
$ 3.57
(50.63%)
4.01M
RNAZTransCode Therapeutics Inc
$ 0.355
(20.09%)
5.82M
NAMSNewAmsterdam Pharma Company NV
$ 22.13
(17.34%)
16.46k
TCTuanChe Ltd
$ 1.93
(16.97%)
640
YIBOPlanet Image International Ltd
$ 3.38
(15.95%)
46.19k
VTVTvTv Therapeutics Inc
$ 12.0634
(-43.10%)
25.21k
TGLTreasure Global Inc
$ 1.436
(-22.38%)
46.69k
LUXHLuxUrban Hotels Inc
$ 0.1526
(-20.10%)
1.18M
CEROCERo Therapeutics Holdings Inc
$ 0.21
(-17.97%)
1.19M
SLNASelina Hospitality PLC
$ 0.0261
(-13.00%)
15.8M
SLNASelina Hospitality PLC
$ 0.0261
(-13.00%)
15.8M
RNAZTransCode Therapeutics Inc
$ 0.355
(20.09%)
5.82M
CGTXCognition Therapeutics Inc
$ 3.57
(50.63%)
4.01M
TLTiShares 20 plus Year Treasury Bond
$ 92.98
(-0.01%)
3.9M
NVDANVIDIA Corporation
$ 113.03
(-0.03%)
2.38M

TSHA Discussion

View Posts
TechandBio TechandBio 2 weeks ago
Started buying shares last year at .77 Riding the houses money now and sold three quarters of my shares at $4.00 range when I saw the double top formation come into play I can see this going to $8.00-$10.00 only on a buyout in the next year. Risky with only a handful of patients dosed and the competition for Rhett but a cunning bet with the management at TSHA. now.
CEO and CMO are best in class. Not a core position but glad I'm in with a few. I hope they have a remedy for these poor kids with Rhett.

$TSHA
👍️0
nsomniyak nsomniyak 3 weeks ago
If these are senior people in prominent management or technical roles it is pretty standard for them to be granted options as part of their compensation package. They vest over 4 years, so it is not an outright giveaway.

Additionally, since these are NEW employees, by definition they have not manipulated the stock down to get a lower option strike price.

I am fine with this very normal comp package.
👍️ 1
ErnieBilco ErnieBilco 3 weeks ago
I'm sorry but granting options to NEW employees is absurd - they shouldn't be entitled to stock options UNTIL their one year on the job.

No wonder why this has trouble making gains for shareholders whom the employees actually work for.
👍️0
LegendaryNomad22 LegendaryNomad22 1 month ago
Weird. Both TSHA and NGNE have gene therapy candidates for Rett and both of them tanked today, despite sharing strong interim results. There's an International Rett Syndrome Foundation meeting today and tomorrow, so I wonder if something happened there to take the wind out of the gene therapy treatment class. Anyone have any knowledge here?
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
Diluted on news
👍️0
Pip611 Pip611 1 month ago
Ouch - what happen?
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
TSHA...GAPPING
👍️0
Tiger Money Tiger Money 1 month ago
Yes, no sorry, didn’t mean to imply that. I was asking if you have other bio names you have on your radar (obviously know about this and Huma). Thanks
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
chart has nothing to do with what sector!!
👍️0
Tiger Money Tiger Money 1 month ago
You have the bios nailed down! Any I should put on my radar? As always, thank you as I sincerely appreciate your help and knowledge. Thanks!
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
TSHA BREAK OUT
👍️0
Monksdream Monksdream 2 months ago
TSHA new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA...HERES 4 DOLLA
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA...READY FOR 4
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA...BIO BEAST BREAKING HEWRE CHAINS
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA HERE WE GO ON THE BREAK OUT!!
👍️0
glenn1919 glenn1919 2 months ago
TSHA......................................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA HERE COMES THE BREAK
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
TSHA...NEXT BIO READY TO BEAST!
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
Taysha may have the real ONE-SHOT genetic cure. It may REALLY work.
Good luck getting any health insurance plan to list this $Million dollar shot in their drug formulary.
👍️0
Monksdream Monksdream 2 months ago
TSHA under $5
👍️0
glenn1919 glenn1919 4 months ago
TSHA..............................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
TSHA..READY TO PUSH TO 4.00
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
TSHA...HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
TSHA..here we go
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
TSHA NEXT BIO BEAST TO RUN TO 3.61 WATCH THE MAGIC
👍️0
FooBarAndGrill FooBarAndGrill 7 months ago
“Dosing the first pediatric patient with Rett syndrome marks an important step forward in our efforts to broaden the clinical evaluation of TSHA-102 to younger patients with earlier stages of Rett syndrome. We are pleased with our progress on expanding the study of TSHA-102 across a broad population of ages and stages of Rett syndrome to bring a potentially transformative treatment option to all patients and families suffering from this devastating disease,” said Sukumar Nagendran, M.D., President, and Head of R&D of Taysha. “The pediatric trial will build on our ongoing REVEAL adolescent and adult trial, where early data demonstrated improvements across multiple clinical domains in adult patients with the most advanced stage of disease. We also plan to expand our U.S. pediatric trial into the U.K. following the recent acceptance of our CTA by the MHRA.”
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Estimated Enrollment : 18 participants
(was 12).
https://classic.clinicaltrials.gov/ct2/show/NCT05606614
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
“Following review of the initial clinical data from the first two adult patients treated with TSHA-102 and Chemistry, Manufacturing, and Controls (CMC) data, Health Canada has authorized our protocol amendment to include adolescent patients aged 12 years and older in the ongoing REVEAL Phase 1/2 adult trial,”
https://ih.advfn.com/stock-market/NASDAQ/taysha-gene-therapies-TSHA/stock-news/92678004/taysha-gene-therapies-announces-expanded-eligibili
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
The P1 TSHA-102 REVEAL Adult Study has been on a slow boat.
Hopefully, the Clinical Updates PR will give the push to finally complete enrollment of the 12 adult female Rett patients needed for the trial.
I'm guessing reluctance to enroll has been based on the one-time injection into the intrathecal space (directly into the Cerebral Spinal Fluid).
It's definitely worth the risk, IMO. Good Luck to All.
👍️0
bikaver bikaver 10 months ago
TSHA.....Definitely headed in the right direction now. A couple more days of downward momo would be great.
👍️0
make it happen make it happen 10 months ago
Cannacord Genuity and Truist Securities both lowered there price targets, never a good thing...
👍️0
make it happen make it happen 10 months ago
Think it's about there. I believe we flush under $3.00 and don't come back to the this price per share PPS till R/S. A ways away but see it happening. JMHO
👍️0
bikaver bikaver 10 months ago
TSHA.....kicking my butt.....next week is make or break!
👍️0
Triple nickle Triple nickle 11 months ago
Good call my .90 are looking ripe
👍️0
bikaver bikaver 11 months ago
Added 3.28 today.
👍️0
bikaver bikaver 11 months ago
TSHA.....Today, all day, was a bull trap. Tomorrow could be Free Falling Friday.
👍️0
bikaver bikaver 11 months ago
TSHA.....The buyers at 2.85-2.91 proves the phrase "There's a sucker born every minute." to be true.
👍️0
richme richme 11 months ago
Looks like the rocket exploded! Was tempted to buy; glad I did not!

Finally bought 2.19 for 6K shares; too soon; down more now to 2.14.
👍️0
Jess070283 Jess070283 11 months ago
Blast off at open?
👍️0
riha riha 11 months ago
at least i don't feel foolish now.

tomorrow though... i might.
👍️0
alchemytrader alchemytrader 11 months ago
be glad you didnt get any. hit 2.91 a/h.
👍️0
alchemytrader alchemytrader 11 months ago
2.85 RIP
👍️0
Triple nickle Triple nickle 11 months ago
Tif function
👍️0
riha riha 11 months ago
I can't get any shorts... fuck
👍️0
bikaver bikaver 11 months ago
TSHA..... added 2.10 short into this strong close.
👍️0
bikaver bikaver 11 months ago
TSHA.....short @ 1.79
👍️0
snave599 snave599 11 months ago
Because it's up 130%.That's why it's halted.
👍️0

Your Recent History

NASDAQ
TSHA
Taysha Gene Therapies
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved